Phibro Animal Health Corporation and Rejuvenate Bio Announce Agreement to Develop Gene Therapy for Mitral Valve Disease in Canines

Author's Avatar
Jun 22, 2022

Phibro Animal Health Corporation (Nasdaq:PAHC) and Rejuvenate Bio, Inc. today announced a collaboration for the development and commercialization of a gene therapy for Mitral Valve Disease (MVD) in canines (dogs).